U.S. Markets open in 9 hrs 19 mins
  • S&P Futures

    +3.25 (+0.10%)
  • Dow Futures

    +31.00 (+0.11%)
  • Nasdaq Futures

    +0.50 (+0.00%)
  • Russell 2000 Futures

    +2.40 (+0.15%)
  • Crude Oil

    +0.17 (+0.44%)
  • Gold

    +4.20 (+0.22%)
  • Silver

    +0.16 (+0.63%)

    +0.0013 (+0.1064%)
  • 10-Yr Bond

    -0.0400 (-4.76%)
  • Vix

    +4.91 (+17.82%)

    +0.0017 (+0.1278%)

    -0.1070 (-0.1021%)

    +7.34 (+0.06%)
  • CMC Crypto 200

    -2.12 (-0.81%)
  • FTSE 100

    -68.27 (-1.16%)
  • Nikkei 225

    -96.17 (-0.41%)

Coronavirus Latest: Thursday, October 8

Regeneron is seeking to receive FDA approval for emergency use of its vaccine, as President Trump says he doesn’t ‘think’ he’s contagious after being released from Walter Reed Hospital. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.

Video Transcript

JEN ROGERS: Moving on, it's another, well, DC story because President Trump contracted the coronavirus, COVID-19. He has been treated with some monoclonal antibodies that he has been trumpeting, really pushing Regeneron and Eli Lilly. The stocks have been moving higher.

And I want to bring in Anjalee Khemlani to help us focus on this a little bit. Because the president had some-- was just glowing about the treatment that he has received, calling it-- going as far as to call it a cure right now. Stocks are higher. What do we know, though, about this?

ANJALEE KHEMLANI: That's correct, Jen. You're right. He did say it felt like a cure when he took it. And that has really given a boost to both stocks, Eli Lilly and Regeneron. Eli Lilly reporting yesterday that it has already filed for an emergency use authorization, and Regeneron following later yesterday as well.

Now we know that Trump has said that he will-- that he has authorized for this to go through. But we know that that is actually in the hands of the FDA, which is already battling with its credibility right now. We know that with hydroxychloroquine and the convalescent plasma, which they pushed through the EUA for hydroxychloroquine, was then revoked.

So there's been so many-- there have been so many steps like this. And then recently, with the vaccine debate, you know, really waiting until the White House to let go of any pushback of waiting for a two-month window observation for those vaccines all playing a role right now.

And all eyes on what the FDA will do with these two EUA applications, knowing that both are in clinical trials still, even though there have been some readouts, right now, some interim readouts, of the data proving that they are, in fact, somewhat effective on hospitalized patients.

So right now, as it stands, Eli Lilly has said that they do have 100,000 doses available for this month and will have up to one million by the end of the year. Meanwhile, Regeneron has about 50,000 right now and will have up to, I believe it is 300,000 by the end of the year.

Regeneron, to the point, is the one that President Trump received when he was at Walter Reed. Eli Lilly is also, by the way, saying just today that they have new information about their rheumatoid arthritis that was developed with Incyte, and that it's proving effective on COVID patients in combination with Gilead's remdesivir.

That's an important point because we know that remdesivir-- you know, studies on that combination have been in the works. And so this is one of those results that we're looking for.

Meanwhile, vaccines also something that we're still looking at right now when it looks to-- when we're looking at sort of the pressure on them. So after the two-month window has been, in fact, sort of accepted at this point, we did hear from Moderna saying that they would have their readout by Thanksgiving.

And also, recently from Health Secretary Alex Azar saying that for now, it looks like we will have enough of doses for all Americans by March. That's important because we know that we've heard in the past that the late Q1, early Q2 timeline has been sort of where it has been the most optimistic for general public to start receiving their doses. So, all this to say, still sort of in a wait and watch period and anxious to see those details, the data that comes out in November.

JEN ROGERS: Anjalee Khemlani, it's a lot going on. Great to get the update from you.